AIM ImmunoTech Inc. (AIM) News
Filter AIM News Items
AIM News Results
|Loading, please wait...|
Latest AIM News From Around the Web
Below are the latest news stories about AIM ImmunoTech Inc that investors may wish to consider to help them evaluate AIM as an investment opportunity.
No summary available.
AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm - 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID OCALA, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immu
AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer
Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and function Strength of data support advancement into Phase 2 clinical study Phase 2 study will be conducted to evaluate immunologic and clinical efficacy of tumor loaded αDC1 vaccine in conjunction with the cisplatin/chemokine modulatory combination regimen OCALA, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AMERICAN ) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today anno...
AIM ImmunoTech <
Live video webcast presentation on Wednesday, January 26th at 10:00 AM ETOCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present
\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.
PharmaCyte Biotech (OTCMKTS:PMCBD) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability. Earnings and Valuation This table compares PharmaCyte Biotech and AIM ImmunoTechs gross revenue, earnings per  The post Critical Review: PharmaCyte Biotech (OTCMKTS:PMCBD) & AIM ImmunoTech (NYSE:AIM) appeared first on ETF Daily News .
Arkadios Wealth Advisors purchased a new stake in shares of AIM ImmunoTech Inc. (NYSE:AIM) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,597 shares of the companys stock, valued at approximately $43,000. Other hedge funds have also recently added 
AIM ImmunoTech’s Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza
OCALA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on December 4-7, 2021. The conference also included research on COVID-19 and respiratory syncytial virus. The Centre for Human Drug Research (CHDR) presented previously announced data from a Phase 1 clinical study to assess th
AIM ImmunoTech (NYSE: AIM) is one of 237 public companies in the Biological products, except diagnostic industry, but how does it contrast to its peers? We will compare AIM ImmunoTech to related companies based on the strength of its dividends, analyst recommendations, risk, valuation, profitability, earnings and institutional ownership. Profitability This table compares AIM ImmunoTech  The post Critical Contrast: AIM ImmunoTech (AIM) & Its Competitors appeared first on ETF Daily News .